Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies
The present invention relates to a compound of one of the formulas I to XXI; a pharmaceutical composition comprising at least one such compound; and the use of at least one such compound in preparing a drug to treat, in a subject, a genetic disease resulting from at least one splicing anomaly.
1. A compound having the following formula:
wherein,
X1 represents a nitrogen atom or a NR11 group, with R11 representing a hydrogen atom or a C1 to C3 alkyl group;
R1 represents a hydrogen atom, an NR11R12 group, or OR12 group with R11 being defined above and R12 representing a hydrogen atom or a C1 to C3 alkyl group;
Y2 represents a nitrogen atom or a CR11 group with R11 selected from the group consisting of a hydrogen atom, a
group and a
group wherein:
R4 represents a hydrogen atom or a C1 to C3 alkyl or a C(═O)NR14R15 group with R4 representing a hydrogen atom or a C1 to C3 alkyl group when R5 or R6 is different than a hydrogen atom;
R5 represents a hydrogen atom, a C(═O)NR14R15 group or a
group with R5 representing a hydrogen atom, when R4 or R6 is different than a hydrogen atom;
R6 represents a hydrogen atom, or a C(═O)NR14R15 group or a
group, and with R6 representing a hydrogen atom when R5 is different than a hydrogen atom or when R4 is different than a hydrogen atom or a C1 to C3 alkyl group; and
R14 and R15 representing independently of the other:
a hydrogen atom, or
a linear or branched C1 to C10 alkyl group, wherein one or more carbon atoms can be substituted by a nitrogen atom, said alkyl group optionally being substituted by one or more —OH and/or ═O groups and/or by:
which may be substituted or unsubstituted, and
R17 represents:
a hydrogen atom, or
a linear or branched C1 to C3 alkyl group, wherein one or more carbon atoms can be substituted by a nitrogen atom, said alkyl group optionally being substituted by one or more —OH and/or ═O groups; and
with Y2 representing a nitrogen atom or a CR11 group with R11 being a hydrogen atom, when R8 or R8′ is different than a nitrogen atom or a CH group and when R8′ is different than a hydrogen or halogen atom;
R8 and R8′ represent a hydrogen atom, a halogen atom, a
group, or a C(═O)NR18R19 group with R18 and R19 representing independently of the other:
a hydrogen atom, or
a linear or branched C1 to C3 alkyl group, wherein one or more carbon atoms can be substituted by a nitrogen atom, said alkyl group optionally being substituted by one or more —OH and/or ═O groups and/or by:
which may be substituted or unsubstituted,
with R8 representing a hydrogen or halogen atom, when Y2 is different than a nitrogen atom or a CH group and when R8′ is different than a hydrogen or halogen atom; and
with R8′ representing a hydrogen or halogen atom, when Y2 is different than a nitrogen atom or a CH group and when R8 is different than a hydrogen or halogen atom;
R21 and R22 represent independently of the other a hydrogen atom or a methyl group;
pharmaceutically acceptable salts of said compounds, stereo isomers thereof and/or mixtures of same.
2. A compound selected from the group consisting of:
N-(3-Diethylamino-propyl)-3-[4-((E)-2-pyridin-4-yl-vinyl)-phenylamino]-benzamide;
N-(3-Methyl-butyl)-3-[4-((E)-2-pyridin-4-yl-vinyl)-phenylamino]-benzamide;
(N-Diethylamino)-3-(1-{3-[4-((E)-2-Pyridin-4-yl-vinyl)-phenylamino]-phenyl}-1H-1,2,3-triazol-4-yl)-methylamine;
3-(1-{3-[4-((E)-2-Pyridin-4-yl-vinyl)-phenylamino]-phenyl}-1H-1,2,3-triazol-4-yl)-propan-1-ol;
N-(3-Diethylamino-propyl)-3-methyl-4-[4-((E)-2-pyridin-4-yl-vinyl)-phenylaminol]-benzamide;
3-Methyl-N-(3-methyl-butyl)-4-[4-((E)-2-pyridin-4-yl-vinyl)-phenylamino]-benzamide;
3-(1-{4-[4-((E)-2-Pyridin-4-yl-vinyl)-phenylamino]-phenyl}-1H-1,2,3-triazol-4-yl)-propan-1-ol;
4-Methyl-N-(3-methyl-butyl)-3-[3-((E)-2-pyridin-4-yl-vinyl)-phenylamino]-benzamide;
N-(3-Diethylamino-propyl)-3-[3-((E)-2-pyridin-4-yl-vinyl)-phenylamino]-benzamide;
N-(3-Methyl-butyl)-3-[3-((E)-2-pyridin-4-yl-vinyl)-phenylamino]-benzamide;
(N-diethylamino)-3-(1-{3-[3-((E)-2-Pyridin-4-yl-vinyl)-phenylamino]-phenyl}-1H-1,2,3-triazol-4-yl)-methylamine;
3-(1-{3-[3-((E)-2-Pyridin-4-yl-vinyl)-phenylamino]-phenyl}-1H-1,2,3-triazol-4-yl)-propan-1-ol;
N-(3-Diethylamino-propyl)-3-methyl-4-[3-((E)-2-pyridin-4-yl-vinyl)-phenylamino]-benzamide;
N-(3-Methyl-butyl)-4-[3-((E)-2-pyridin-4-yl-vinyl)-phenylamino]-benzamide;
N-(3-Diethylamino-propyl)-3-[3-((E)-2-pyridin-2-yl-vinyl)-phenylamino]-benzamide;
N-(3-Methyl-butyl)-3-[3-((E)-2-pyridin-2-yl-vinyl)-phenylamino]-benzamide;
3-(1-{3-[4-((E)-2-Pyridin-4-ylvinyl)-phenylamino]-phenyl}-1H-1,2,3-triazol-4-yl)-propan-1-ol;
N-(3-Diethylamino-propyl)-4-[3-((E)-2-pyridin-2-yl-vinyl)-phenylamino]-benzamide;
N-(3-Methyl-butyl)-3-methyl-4-[3-((E)-2-pyridin-2-yl-vinyl)-phenylamino]-benzamide; and
3-(1-{3-[3-((E)-2-Pyridin-2-ylvinyl)-phenylamino]-phenyl}1H-1,2,3-triazol-4-yl)-propan-1-ol.
3. A pharmaceutical composition, wherein it comprises the compound of claim 1 and, optionally, a pharmaceutically acceptable support.